{"schema_version":"alpha-company-profile-public-v2","slug":"abivax-s-a","canonical_url":"https://registry.alpha.ac/companies/abivax-s-a","published_on":"2026-09-05T21:41:36.362943+00:00","last_reviewed_on":"2026-09-05T21:41:36.362943+00:00","identity":{"legal_name":"Abivax S.A.","display_name":"Abivax S.A.","headline":"Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer.","description":"Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and COVID-19. It is also being assessed in Phase IIa trials for rheumatoid arthritis, and has successfully concluded Phase IIa studies demonstrating viral re","ten_second_view":"This Company Profile publishes only Alpha's canonical identity and evidence-backed public leadership records. Unavailable fields are not inferred.","legal_form":"Not publicly asserted","incorporation":"Not publicly asserted","headquarters":"US","headquarters_address":{"locality":"Not publicly asserted","region":null,"country":"US"},"operating_presence":["US"],"website":"","cik":"0001956827","logo":"https://cdn.brandfetch.io/ticker/aavxf/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","logo_source":"brandfetch","profile_mark":{"src":"https://cdn.brandfetch.io/ticker/aavxf/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","alt":"Abivax S.A. logo","width":256,"height":256,"source":"brandfetch"}},"entity_status":{"ownership_type":"unknown","listing_status":"listed","label":"Public listing published","explanation":"The canonical public record includes at least one active security listing.","source_id":"alpha-canonical-company-record","reviewed_on":"2026-09-05T21:41:36.362943+00:00"},"security_listings":[{"ticker":"AAVXF","exchange":"OTC","exchange_display":"OTC","mic":"OTCM","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"},{"ticker":"ABVX","exchange":"NASDAQ","exchange_display":"NASDAQ","mic":"XNAS","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"},{"ticker":"ABVX","exchange":"EURONEXT PARIS","exchange_display":"EURONEXT PARIS","mic":"XPAR","currency":"EUR","security_type":"equity","listing_status":"active","is_primary":false,"source_id":"alpha-canonical-company-record"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market data is not published in this Company Profile."},"profile_tags":["Canonical identity","Public leadership"],"trust_summary":"Canonical identity published; broader company intelligence is not asserted.","facts":[{"label":"Legal name","value":"Abivax S.A.","source_id":"alpha-canonical-company-record"},{"label":"Country","value":"US","source_id":"alpha-canonical-company-record"},{"label":"Sector","value":"Healthcare","source_id":"alpha-canonical-company-record"},{"label":"Industry","value":"Biotechnology","source_id":"alpha-canonical-company-record"}],"operating_model":{"eyebrow":"Operating record","title":"Published operating structure","units":[]},"governance":{"summary":"Only current, confirmed leadership roles with public evidence are included in the canonical projection.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","disclosures":[]},"alpha_opinion":{"status":"Not published","label":"No Alpha opinion published","explanation":"This identity record is not an Alpha rating, score, or investment opinion."},"report":{"status":"Not published","label":"No governed report published","explanation":"No governed company report is attached to this profile.","href":null},"actions":[],"related_records":[],"evidence":[{"id":"alpha-canonical-company-record","label":"Alpha canonical company public projection","href":"/api/public/companies/abivax-s-a","source_type":"canonical_identity","supports":["Company identity","Published leadership","Entity status boundary"],"status":"published","reviewed_on":"2026-09-05T21:41:36.362943+00:00"}],"permissions":[{"label":"Public retrieval","allowed":true},{"label":"Agent retrieval","allowed":true},{"label":"Redistribution","allowed":false},{"label":"Model training","allowed":false},{"label":"Relationship pathfinding","allowed":false},{"label":"Direct contact","allowed":false}],"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"trust":{"schema_version":"alpha-profile-trust-v1","verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":15,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"aggregation":{"schema_version":"alpha-claim-aggregation-v1","published_claim_count":15,"under_review_claim_count":1,"owner_supplied_claim_count":0,"evidence_record_count":2,"distinct_source_count":2,"conflicts":[],"conflict_count":0,"headline_conflict_count":0,"internal_review_conflict_count":0,"contradiction_types":[],"headline_conflict_types":[],"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":15,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"coverage":{"schema_version":"alpha-coverage-metric-v1","published_claims":15,"corroborated_claims":0,"sources":2,"distinct_sources":2,"role_claims":0,"last_reviewed_at":"2026-09-05T21:41:36.362943+00:00","observed_at":"2026-09-05T21:41:36.362943+00:00","freshness_days":0}},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"}},"projection":{"schema_version":"alpha-profile-projection-v5","entity":{"kind":"company","slug":"abivax-s-a","canonical_url":"https://registry.alpha.ac/companies/abivax-s-a"},"publication":{"published_at":"2026-09-05T21:41:36.362943+00:00","last_reviewed_at":"2026-09-05T21:41:36.362943+00:00","as_of":"2026-09-05T21:41:36.362943+00:00"},"representations":{"html":{"href":"https://registry.alpha.ac/companies/abivax-s-a","media_type":"text/html"},"json":{"href":"https://registry.alpha.ac/api/public/companies/abivax-s-a","media_type":"application/json"},"markdown":{"href":"https://registry.alpha.ac/companies/abivax-s-a.md","media_type":"text/markdown"},"structured_data":{"embedded":true,"media_type":"application/ld+json"},"share_image":null},"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false}},"canonical_profile":{"schema_version":"alpha-company-profile-public-v1","slug":"abivax-s-a","canonical_url":"https://registry.alpha.ac/companies/abivax-s-a","as_of":"2026-09-05T21:41:36.362943+00:00","last_reviewed_at":"2026-09-05T21:41:36.362943+00:00","identity":{"legal_name":"Abivax S.A.","display_name":"Abivax S.A.","description":"Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and COVID-19. It is also being assessed in Phase IIa trials for rheumatoid arthritis, and has successfully concluded Phase IIa studies demonstrating viral re","jurisdiction":null,"country":"US","sector":"Healthcare","industry":"Biotechnology","website":null,"website_provenance":null,"logo_url":null,"logo_media":null,"status":"active","cik":"0001956827","entity_subtype":null,"legal_entity_status":null},"security_listings":[{"mic":"OTCM","ticker":"AAVXF","currency":null,"exchange":"OTC","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"1c0827da-fa85-478b-afd1-4d0dcd7ec669","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-09T14:36:02+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"OTC Markets","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"},{"mic":"XNAS","ticker":"ABVX","currency":null,"exchange":"NASDAQ","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"e60b1cbc-14b2-4193-87e5-6201fe94f17d","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-11T00:28:32+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"NASDAQ","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"},{"mic":"XPAR","ticker":"ABVX","currency":"EUR","exchange":"EURONEXT PARIS","sort_key":1,"valid_to":null,"confidence":0.95,"is_primary":false,"listing_id":"d905f8b1-e11b-4ae7-8323-007c1f2dd330","source_url":"https://live.euronext.com/en/product/equities/FR0012333284-XPAR","valid_from":null,"observed_at":"2026-09-02T01:59:51.783468+00:00","source_name":"euronext_product_directory","source_tier":1,"exchange_name":"Euronext Paris","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:59:51.783468+00:00"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market observations are unpublished. Listing identity remains available from the governed source set."},"index_memberships":[],"index_membership_history":[],"index_membership_contract":{"schema_version":"alpha-index-membership-public-v1","as_of_date":"2026-09-12","tracked_universe_complete":false,"permissions":{"public_retrieval":true,"agent_retrieval":false,"redistribution":false,"model_training":false},"limitations":["Only source-backed memberships with an explicit public redistribution basis are returned.","Absence from Alpha tracked indices does not establish absence from every market index.","Provider announcements and effective membership are represented as distinct states.","Alpha AI 100 is not published as a current public index membership."]},"leadership":{"board":[{"person_slug":"sylvie-gr-goire","display_name":"Sylvie Grégoire","role_category":"director","title":"Board Chair, Independent Director","committee":null,"is_board_chair":true,"is_independent":true,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"camilla-soenderby","display_name":"Camilla Soenderby","role_category":"director","title":"Independent Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"corinna-zur-bonsen-thomas","display_name":"Corinna zur Bonsen-Thomas","role_category":"director","title":"Independent Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"dominik-h-chli","display_name":"Dominik Höchli","role_category":"director","title":"Independent Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"june-lee","display_name":"June Lee","role_category":"director","title":"Independent Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"marc-de-garidel","display_name":"Marc de Garidel","role_category":"director","title":"Chief Executive Officer and Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"troy-ignelzi-abivax-s-a","display_name":"Troy Ignelzi","role_category":"director","title":"Independent Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null}],"executives":[{"person_slug":"didier-blondel","display_name":"Didier Blondel","role_category":"executive","title":"Executive Vice President, Chief Financial Officer and Board Secretary","committee":null,"is_board_chair":false,"is_independent":null,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"fabio-cataldi","display_name":"Fabio Cataldi","role_category":"executive","title":"Chief Medical Officer","committee":null,"is_board_chair":false,"is_independent":null,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null},{"person_slug":"marc-de-garidel","display_name":"Marc de Garidel","role_category":"executive","title":"Chief Executive Officer and Director","committee":null,"is_board_chair":false,"is_independent":null,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.95,"evidence":{"document_title":"SEC 20-F 0001956827-26-000012","source_url":"https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm","source_type":"sec_20f","published_at":"2026-03-23T00:00:00+00:00","effective_date":"2026-03-23","last_checked_at":"2026-09-05T21:41:36.362943+00:00"},"headshot_url":null}],"coverage":{"schema_version":"alpha-leadership-coverage-v1","board_roster_scope":"def_14a_current_directors","executive_roster_scope":"disclosed_officers_only","neo_set_status":"NOT_ASSERTED","board_roster_complete":false,"neo_set_complete":false,"notes":["Empty executives is NOT_ASSERTED, not a complete named-executive-officer set.","Form 4 occupancy is not a DEF 14A board.","Unconfirmed current sec_proxy DEF 14A directors may project. Confirmed is not required.","Unconfirmed current executives with first-party issuer evidence (source_url + effective date) may project.","Company-page directors do not require people.public_profile_enabled.","Completeness compares the latest first-party roster with the public projection; a source older than 180 days is STALE.","Do not remap HONA to HON 0000773840. Do not merge XOM 0000034088 with 0002115436.","Person match is projection-only. Name-only Person merges are forbidden."],"completeness":{"reasons":["NO_LEADERSHIP_SOURCE"],"board_completeness":"NOT_REVIEWED","completeness_schema":"alpha-leadership-completeness-v1","executive_team_completeness":"NOT_REVIEWED"},"parser_bleed_excluded":true,"former_titles_excluded":true,"identity_merge_forbidden":true,"form4_occupancy_is_not_board":true}},"permissions":{"classification":"open_public_projection","public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false},"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"structured_data":{"@context":["https://schema.org",{"alpha":"https://alpha.ac/ns/","indexMembership":"alpha:indexMembership","indexProvider":"alpha:indexProvider","indexMembershipStatus":"alpha:indexMembershipStatus","indexEffectiveDate":"alpha:indexEffectiveDate","indexAnnouncementDate":"alpha:indexAnnouncementDate","indexRemovalDate":"alpha:indexRemovalDate","lastVerifiedAt":"alpha:lastVerifiedAt","verificationStatus":"alpha:verificationStatus","evidence":"alpha:evidence"}],"@type":"ProfilePage","@id":"https://registry.alpha.ac/companies/abivax-s-a#profile","url":"https://registry.alpha.ac/companies/abivax-s-a","dateModified":"2026-09-05T21:41:36.362943+00:00","mainEntity":{"@type":"Organization","@id":"https://registry.alpha.ac/companies/abivax-s-a#organization","legalName":"Abivax S.A.","name":"Abivax S.A.","description":"Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and COVID-19. It is also being assessed in Phase IIa trials for rheumatoid arthritis, and has successfully concluded Phase IIa studies demonstrating viral re","url":"https://registry.alpha.ac/companies/abivax-s-a","addressCountry":"US","indexMembership":[],"member":[{"@type":"OrganizationRole","roleName":"Board Chair, Independent Director","member":{"@type":"Person","name":"Sylvie Grégoire","url":"https://registry.alpha.ac/people/sylvie-gr-goire"}},{"@type":"OrganizationRole","roleName":"Independent Director","member":{"@type":"Person","name":"Camilla Soenderby","url":"https://registry.alpha.ac/people/camilla-soenderby"}},{"@type":"OrganizationRole","roleName":"Independent Director","member":{"@type":"Person","name":"Corinna zur Bonsen-Thomas","url":"https://registry.alpha.ac/people/corinna-zur-bonsen-thomas"}},{"@type":"OrganizationRole","roleName":"Independent Director","member":{"@type":"Person","name":"Dominik Höchli","url":"https://registry.alpha.ac/people/dominik-h-chli"}},{"@type":"OrganizationRole","roleName":"Independent Director","member":{"@type":"Person","name":"June Lee","url":"https://registry.alpha.ac/people/june-lee"}},{"@type":"OrganizationRole","roleName":"Chief Executive Officer and Director","member":{"@type":"Person","name":"Marc de Garidel","url":"https://registry.alpha.ac/people/marc-de-garidel"}},{"@type":"OrganizationRole","roleName":"Independent Director","member":{"@type":"Person","name":"Troy Ignelzi","url":"https://registry.alpha.ac/people/troy-ignelzi-abivax-s-a"}},{"@type":"OrganizationRole","roleName":"Executive Vice President, Chief Financial Officer and Board Secretary","member":{"@type":"Person","name":"Didier Blondel","url":"https://registry.alpha.ac/people/didier-blondel"}},{"@type":"OrganizationRole","roleName":"Chief Medical Officer","member":{"@type":"Person","name":"Fabio Cataldi","url":"https://registry.alpha.ac/people/fabio-cataldi"}},{"@type":"OrganizationRole","roleName":"Chief Executive Officer and Director","member":{"@type":"Person","name":"Marc de Garidel","url":"https://registry.alpha.ac/people/marc-de-garidel"}}]},"mainEntityOfPage":"https://registry.alpha.ac/companies/abivax-s-a"}},"canonical_source":"aegis_canonical"}